Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action.
about
Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.The presynaptic component of the serotonergic system is required for clozapine's efficacy.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.Newer molecules in the treatment of schizophrenia: A clinical updateGlutamatergic neurometabolites in clozapine-responsive and -resistant schizophreniaRETRACTED: Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients.Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophreniaModulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.Reduction of Pavlovian Bias in Schizophrenia: Enhanced Effects in Clozapine-Administered Patients.Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Classics in chemical neuroscience: clozapine.Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study.NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER.Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression.D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Functional dysconnectivity of the limbic loop of frontostriatal circuits in first-episode, treatment-naive schizophrenia.Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.The GlyT1 Inhibitor Bitopertin Ameliorates Allodynia and Hyperalgesia in Animal Models of Neuropathic and Inflammatory Pain.Neurophysiological Effects of Bitopertin in SchizophreniaEradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
P2860
Q28277784-AF8F502C-A1ED-4A0D-8F15-1891476343E4Q30382281-42387919-59CC-4DDB-914D-927F88DBCE24Q30471071-1878753D-F61E-4804-B5FF-BC21F77C9BA0Q30473410-D5AA32FC-BE35-462E-B760-1129077F5B5EQ34274859-260C02DB-A493-4619-B408-E307BC9F8092Q34381226-ECB9FBD8-1CC7-479C-A2D3-FDA723A9B46EQ34843883-B8C7FB28-DBCB-4163-8EB9-30E63E30A68CQ35626964-2E6AF82F-3F2E-4EFE-9193-439186A5DEA1Q35662070-8CDCB633-40DF-4702-8AE9-F292876F009BQ36234271-08E52B22-AD4C-412E-93B7-1ADCAB664715Q36642660-D4D237BC-D182-41D0-BC70-C52756EF80D2Q36803130-2B5DF9BD-730B-44B2-A230-E2945A0433DBQ36886717-ADAC3CDB-5FE6-4870-B974-DB539B8BF341Q37025878-408FA03A-B671-4DE5-A539-996EC827E078Q37268726-E6A7AF50-9594-42ED-89E3-AE724D76D821Q37343344-16C3CC41-0636-46EB-B789-E62B21569024Q37560810-121112DC-CF26-4177-AB2E-B5AAE3A7A565Q38750121-E926943A-DCED-459D-AF50-BA68097EB3B1Q38917991-8DDD186F-D0AE-48E2-BD19-E37BC2069CC5Q39233330-EBD2F32C-59D1-4F05-94E1-4748A81A3EF3Q47388815-C62D857C-D0D5-4A1A-9BA9-92AB2478650CQ48219402-59C00C1E-2DDC-4C0A-96D2-A42278FF9519Q49632560-C85797F0-DB92-4B71-9CD7-0A122D5CA817Q57828993-883EAD5F-B760-4E13-9578-E689BE0EF9C3Q59138279-8D9D447D-2215-4882-8A0E-75580EF4B93B
P2860
Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Inhibition of system A-mediate ...... ions for mechanisms of action.
@en
type
label
Inhibition of system A-mediate ...... ions for mechanisms of action.
@en
prefLabel
Inhibition of system A-mediate ...... ions for mechanisms of action.
@en
P2093
P2860
P356
P1433
P1476
Inhibition of system A-mediate ...... ions for mechanisms of action.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.MP.4001552
P407
P577
2005-03-01T00:00:00Z